Evotec SE EVO
NASDAQ EVO
$1.67 +0.05 (+3.09%)
At close: Sep 17, 2026 · 4:00 PM EDT

Evotec SE (EVO) Capital Leases (2009 - 2022)

Evotec SE's (EVO) quarterly Capital Leases came in at -$152.4 million in Q2 2022, up 1.99% quarter-over-quarter from -$155.5 million in Q4 2021.

Analysis

Evotec SE (EVO) Capital Leases (2009 - 2022) Analysis & Trends

Evotec SE has disclosed Capital Leases across 4 years of filings, most recently posting -$152.4 million for Q2 2022.

  • In Q2 2022, Capital Leases changed N/A year-over-year to -$152.4 million; the TTM figure through Jun 2022 stood at -$152.4 million (changed N/A YoY), while the FY2021 annual figure was -$160.9 million, changed N/A from the prior year.
  • Capital Leases came in at -$152.4 million for Q2 2022 at Evotec SE, up from -$155.5 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of -$152.4 million in Q2 2022 to a low of -$155.5 million in Q4 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Iqvia Holdings 44.72 Bn 42.64 Bn 1.44 Bn
2 Medpace Holdings 17.37 Bn 16.87 Bn 201.64 Mn
3 Icon 13.65 Bn 12.72 Bn 479.29 Mn
4 Charles River Laboratories International 13.13 Bn 12.94 Bn 452.07 Mn
5 Fortrea Holdings 1.89 Bn 1.72 Bn 139.20 Mn
6 Evotec SE 574.75 Mn 148.87 Mn -
7 Ginkgo Bioworks Holdings 439.63 Mn 355.09 Mn 18.44 Mn
8 Champions Oncology 69.43 Mn 65.03 Mn 7.70 Mn
9 MindWalk Holdings 51.76 Mn 46.29 Mn 1.61 Mn
10 VivoSim Labs 1.37 Mn 1.37 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 -152.44 Mn
Dec 31, 2021 -155.54 Mn
Sep 30, 2010 61,981.09
Jun 30, 2010 91,788.30
Mar 31, 2010 149,548.66
Dec 31, 2009 194,928.92
Jun 30, 2009 276,414.61
Mar 31, 2009 359,626.73